Clinical efficacy of primary human papillomavirus (HPV) screening with partial genotyping for HPV-16 and HPV-18 subtypes in women from 25 years old

Introduction: Cervical screening programmes differ in the age of women recommended for primary human papillomavirus (HPV) testing. This study aims to determine clinical efficacy and impact 14-high-risk HPV DNA testing from 25 years old. Method: was a retrospective analysis data collected prospectively or older who attended hospital-based gynaecology clinics cervical screening. Women with history neoplasia abnormal cytology were excluded. High-risk partial genotyping HPV-16 HPV-18 performed on cobas 4800 System (Roche Diagnostics International AG, Rotkreuz, Switzerland). tested positive 12 other high-risk subtypes (HPV-12 other) had reflex test. Positive included and/or HPV-18, HPV-12 abnormalities equal greater than atypical squamous cells undetermined significance, repeated at months. detection colposcopy referral rates, high-grade determined. Results: Of 10,967 studied, 822 (7.50%) positive. The overall discharge rate routine according protocol 93.1%. Colposcopy 4.4%. detected 41 intraepithelial grade 2+ (CIN2+) (0.37%) 31 (0.28%) CIN3+. number colposcopies needed per case CIN2+ 9.5, similar below above 30 CIN3+ positivity 8.5, compared 17.0 categories (P=0.040). cytology. Conclusion: Taking as endpoints, Singapore can be extended include Keywords: cancer screening, neoplasia, colposcopy, obstetrics gynaecology, Pap smear